Tetra Bio-Pharma expects to bring in $675M in net sales by 2027 from its CBD-based cancer pain drug



Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) SVP of Commercial Strategy Dania Scott tells Proactive the …

Be the first to comment

Leave a Reply

Your email address will not be published.


*